Antidiabetische Wirkung der Inhaltsstoffe von Momordica charantia

Zusammenfassung

Momordica charantia L. (Cucurbitaceae), allgemein bekannt als Bittergurke oder Bittermelone, weist eine lange Geschichte in der Behandlung von Diabetes und dessen Komplikationen auf. Über ihre antidiabetische Wirkung und ihre positive Wirkung auf den Blutzucker und die Lipidkonzentration wurde in zahlreichen In-vitro- und In-vivo-Studien berichtet, die für die beobachteten Auswirkungen verantwortlichen Substanzen sind indes noch nicht hinreichend beschrieben. In den letzten Jahren konzentrierte sich die Forschung immer mehr auf die besonderen Triterpenoide vom Cucurbitan-Typ, die in den Früchten und anderen Teilen der Pflanze reichlich vorhanden sind. Die vorliegende Arbeit fasst die antidiabetische Wirkung der sogenannten Momordicoside zusammen und erörtert ihre Verwendung in kommerziellen Präparaten.

Abstract

Momordica charantia L. (Cucurbitaceae), commonly known as bitter gourd or bitter melon, has a long history in the treatment of diabetes and its complications. Its antidiabetic properties and its beneficial effects on blood glucose and lipid concentrations have been reported in numerous in vitro and in vivo studies, but the compounds responsible for the observed effects have not yet been adequately described. In the last years, research more and more focused on the particular cucurbitane-type triterpenoids abundant in the fruits and other parts of the plant. The present work summarizes the antidiabetic activities reported for the so-called momordicosides and discusses their use in commercial preparations.

Schlüsselwörter

Momordica charantia - Bittermelone - Diabetes mellitus - Momordicoside

Key words

Momordica charantia - bitter melon - diabetes mellitus - momordicosides

Publikationsverlauf

Artikel online veröffentlicht:
13. Juni 2023

• Literatur

• 1 International Diabetes Federation. 10th edition. IDF Diabetes Atlas 2021. Im Internet: www.diabetesatlas.org
• 2 Liu Z, Gong J, Huang W. et al. The effect of Momordica charantia in the treatment of diabetes mellitus: A review. Evid Based Complement Altern Med 2021; e3796265
• 3 Walters TW, Decker-Walters DS. Balsam-pear (Momordica charantia, Cucurbitaceae). Econ Bot 1988; 42: 286-288
• 4 Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L (Cucurbitaceae). Phytomedicine 1996; 2: 349-362
• 5 Çiçek SS. Momordica charantia L. – Diabetes-related bioactivities, quality control, and safety considerations. Front Pharmacol 2020; 13: 904643
• 6 Tan SP, Kha TC, Parks SE. et al. Bitter melon (Momordica charantia L.) bioactive composition and health benefits: A review. Food Rev Int 2016; 32: 181-202
• 7 Yin J, Zhang H, Ye J. Traditional Chinese Medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008; 8: 99-111
• 8 Bailey CJ, Day C, Leatherdale BA. Traditional treatments for diabetes from Asia and the West Indies. Pract Diabetes Int 1986; 3: 190-192
• 9 Ma J, Krynitsky AJ, Grundel E. et al. Quantitative determination of cucurbitane-type triterpenes and triterpene glycosides in dietary supplements containing bitter melon (Momordica charantia) by HPLC-MS/MS. AOAC Int 2012; 95: 1597-1608
• 10 Leung L, Birtwhistle R, Kotecha J. et al. Anti-diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): A mini review. Br J Nutr 2009; 102: 1703-1708
• 11 Ooi CP, Yassin Z, Hamid T-A. Momordica charantia for type 2 diabetes mellitus. Cochrane Database Syst 2012; Rev. 8.
• 12 Yin RV, Lee NC, Hirpara H. et al. The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: A systematic review and meta-analysis. Nutr Diabetes 2014; 4: e145
• 13 Peter EL, Kasali FM, Deyno S. et al. Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: Systematic review and meta-analysis. J Ethnopharmacol 2019; 231: 311-324
• 14 Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): A review of efficacy and safety. Am J Health-Syst Pharm 2003; 60: 356-359
• 15 Krawinkel MB, Keding GB. Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia. Nutr. Rev 2006; 64: 331-337
• 16 Shetty AK, Suresh Kumar G, Sambaiah K. et al. Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats. Plant Foods Hum Nutr 2005; 60: 109-112
• 17 Singh N, Tyagi SD, Agarwal SC. Effects of long term feeding of acetone extract of Momordica charantia (whole fruit powder) on alloxan diabetic albino rats. Indian J Physiol Pharmacol 1989; 33: 97-100
• 18 Ahmed I, Adeghate E, Cummings E. et al. Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rat. Mol Cell Biochem 2004; 261: 63-70
• 19 Efird JT, Choi YM, Davies SW. et al. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health 2014; 11: 2328-2345
• 20 Fuangchan A, Sonthisombat P, Seubnukarn T. et al. Hypoglycemic effect of bitter melon compared with metformin in newly diagnosed type 2 diabetes patients. J Ethnopharmacol 2011; 134: 422-428
• 21 Zänker K, Mang B, Wolters M. et al. Personalized diabetes and cancer medicine: A rationale for anti-diabetic nutrition (bitter melon) in a supportive setting. Curr Cancer Ther 2012; Rev. 8: 66-77
• 22 Lotlikar MM, Rajarama Rao MR. Pharmacology of a hypoglycaemic principle isolated from the fruits of Momordica charantia Linn. Indian J Pharm 1966; 28: 129-133
• 23 Khanna P, Jain SC, Panagariya A. et al. Hypoglycemic activity of polypeptide-p from a plant source. J Nat Prod 1981; 44: 648-655
• 24 Handa G, Singh J, Sharma MI. et al. Hypoglycaemic principle of Momordica charantia seeds. Indian J Nat Prod 1990; 6: 16-19
• 25 Desai S, Tatke P, Mane T. et al. Isolation, characterization and quantitative HPLC-DAD analysis of components of charantin from fruits of Momordica charantia. Food Chem 2021; 345: 128717
• 26 Pahlavani N, Roudi F, Zakerian M. et al. Possible molecular mechanisms of glucose-lowering activities of Momordica charantia (karela) in diabetes. J Cell Biochem 2019; 120: 10921-10929
• 27 Jia S, Shen M, Zhang F. et al. Recent advances in Momordica charantia: Functional components and biological activities. Int J Mol Sci 2017; 18: 2555
• 28 Saeed F, Afzaal M, Niaz B. et al. Bitter melon (Momordica charantia): A natural healthy vegetable. Int J Food Prop 2018; 21: 1270-1290
• 29 Sun L, Zhang X, Dong L. et al. The triterpenoids of the bitter gourd (Momordica charantia) and their pharmacological activities: A review. J Food Compost Anal 2021; 96: 103726
• 30 Dutta PK, Chakravarty AK, Chaudhury US. et al. Vicine, a favism-inducing toxin from Momordica charantia Linn seeds. Indian J Pharm 1981; 20B: 669-671
• 31 Barron D, Kaouadji M, Mariotte AM. Etude comparative de deux cucurbitacées a usage medicinal. Planta Med 1982; 46: 184-186
• 32 Zhang C, Chen H, Bai W. Characterization of Momordica charantia L. polysaccharide and its protective effect on pancreatic cells injury in STZ-induced diabetic mice. Int J Biol Macromol 2018; 115: 45-52
• 33 Harinantenaina L, Tanaka M, Takaoka S. et al. Momordica charantia constituents and antidiabetic screening of the isolated major compounds. Chem Pharm Bull 2006; 54: 1017-1021
• 34 Jiang B, Ji M, Liu W. et al. Antidiabetic activities of a cucurbitane-type triterpenoid compound from Momordica charantia in alloxan-induced diabetic mice. Mol Med Rep 2016; 14: 4865-4872
• 35 Tan M-J, Ye J-M, Turner N. et al. Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem Biol 2008; 15: 263-273
• 36 Cheng H-L, Huang H-K, Chang C-I. et al. A cell-based screening identifies compounds from the stem of Momordica charantia that overcome insulin resistance and activate AMP-activated protein kinase. J Agric Food Chem 2008; 56: 6835-6843
• 37 Chang C-I, Tseng H-I, Liao Y-W. et al. In vivo and in vitro studies to identify the hypoglycaemic constituents of Momordica charantia wild variant WB24. Food Chem 2011; 125: 521-528
• 38 Hsiao P-C, Liaw C-C, Hwang S-Y. et al. Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia. J Agric Food Chem 2013; 61: 2979-2986
• 39 Han J-H, Tuan N Q, Park M-H. et al. Cucurbitane triterpenoids from the fruits of Momordica charantia improve insulin sensitivity and glucose homeostasis in streptozotocin-induced diabetic mice. Mol Nutr Food Res 2018; 62: 1700769
• 40 Lo H-Y, Ho T-Y, Lin C. et al. Momordica charantia and its novel polypeptide regulate glucose homeostasis in mice via binding to insulin receptor. J Agric Food Chem 2013; 61: 2461-2468
• 41 Lo H-Y, Ho T-Y, Li C-C. et al. A novel insulin receptor-binding protein from Momordica charantia enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway. J Agric Food Chem 2014; 62: 8952-8961
• 42 Lo H-Y, Li C-C, Ho T-Y. et al. Identification of the bioactive and consensus peptide motif from Momordica charantia insulin receptor-binding protein. Food Chem 2016; 204: 298-305
• 43 Yang Y-S, Wu N-Y, Kornelius E. et al. A randomized, double-blind, placebo-controlled trial to evaluate the hypoglycemic efficacy of the mcIRBP-19-containing Momordica charantia L. fruit extracts in the type 2 diabetic subjects. Food Nutr. Res 2022; 66: 3685
• 44 Nhiem NX, Kiem PV, Minh CV. et al. Cucurbitane-type triterpene glycosides from the fruits of Momordica charantia. Magn Reson Chem 2010; 48: 392-396
• 45 Kulkarni P, Lohidasan S, Mahadik K. Isolation, characterisation and investigation of in vitro antidiabetic and antioxidant activity of phytoconstituents from fruit of Momordica charantia Linn. Nat Prod Res 2021; 35: 1035-1037
• 46 Shivanagoudra SR, Perera WH, Perez JL. et al. Cucurbitane-type compounds from Momordica charantia: Isolation, in vitro antidiabetic, anti-inflammatory activities and in silico modeling approaches. Bioorg Chem 2019; a; 87: 31-42
• 47 Shivanagoudra SR, Perera WH, Perez JL. et al. In vitro and in silico elucidation of antidiabetic and anti-inflammatory activities of bioactive compounds from Momordica charantia L. Bioorg Med Chem 2019; b; 27: 3097-3109
• 48 Perera WH, Shivanagoudra SR, Pérez JL. et al. Anti-inflammatory, antidiabetic properties and in silico modeling of cucurbitane-type triterpene glycosides from fruits of an Indian cultivar of Momordica charantia L. Molecules 2021; 26: 1038
• 49 Chen J-C, Lau CB-S, Chan JY-W. et al. The antigluconeogenic activity of cucurbitacins from Momordica charantia. Planta Med 2015; 81: 327-332
• 50 Ma J, Whittaker P, Keller AC. et al. Cucurbitane-type triterpenoids from Momordica charantia. Planta Med 2010; 76: 1758-1761
• 51 Keller AC, Ma J, Kavalier A. et al. Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro. Phytomedicine 2011; 19: 32-37
• 52 Lee YH, Yoon S-Y, Baek J. et al. Metabolite profile of cucurbitane-type triterpenoids of bitter melon (fruit of Momordica charantia) and their inhibitory activity against protein tyrosine phosphatases relevant to insulin resistance. J Agric Food Chem 2021; 69: 1816-1830